A Multicenter, Randomized, Double-blind, Parallel, Excipient-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of SHR0302Base in Subjects With Nonsegmental Vitiligo
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs Ivarmacitinib (Primary)
- Indications Vitiligo
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 03 Feb 2025 New trial record